🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Petrobras (PBR) Receives Court Approval For Asset Sales

Published 06/09/2019, 09:47 PM
Updated 07/09/2023, 06:31 AM
SHEL
-
EQNR
-
PBR
-
EQNR
-
TTE
-

Bringing in pleasant news for Petrobras (NYSE:PBR) , the Brazilian Supreme Court recently lifted the suspension order on the company that put a pause on its asset divestiture program. The court’s ruling brought relief to the state-held energy giant as the suspension order had posed a severe threat to the company’s aim of mitigating huge debt.

In May, the court had suspended the sale of the TAG pipeline unit, eight refineries and the Araucaria Nitrogenous fertilizer business, putting Petrobras’ divestment plans in jeopardy. Supreme Court Justice Edson Fachin halted the $8.6-billion sale of the TAG unit to Engie SA-led consortium, arguing that the divestments of subsidiaries by state-owned companies needed congressional approval. Markedly, the TAG sale is supposed to be the largest-ever single asset sale for the Brazilian energy giant, which has been making serious efforts to trim its huge debt burden.

Marking a major victory for the Bolsonaro government and Petrobras, the court recently ruled that state-held companies do not require congressional approval to jettison their subsidiaries. The ruling is a boon for other state-owned firms like Eletrobras, which is also contemplating to offload some of its assets.

For Petrobras, the divestment plans are is in sync with the aim of cutting debt levels. Notably, while the company’s net debt of $100 billion peaked in 2015, concentrated efforts to lower leverage, boost liquidity through operational efficiency and divestment of non-core assets have helped Petrobras in deleveraging to a considerable extent. In 2018, its net debt declined to $69.4 billion from $84.9 billion a year ago and $96.4 billion in 2016. The finalization of the sale of TAG assets and other divestments are likely to give a considerable boost to the company’s financials.

As we know, Petrobras revved up its five-year plan in March, and now intends to offload $26.9 billion through 2023, streamline portfolio and sharpen focus on other profitable segments for achieving top-tier results. The firm is entering into various strategic partnerships with foreign oil giants to drive exploration momentum. In this regard, the Zacks Rank #3 (Hold) company inked deals with major players like TOTAL S.A. (NYSE:TOT) , Royal Dutch Shell (LON:RDSa) plc RDS.A and Equinor ASA (NYSE:EQNR) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Petroleo Brasileiro S.A.- Petrobras (PBR): Free Stock Analysis Report

Royal Dutch Shell PLC (RDS.A): Free Stock Analysis Report

TOTAL S.A. (TOT): Free Stock Analysis Report

Statoil ASA (OL:EQNR): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.